Decode the unseen.

//

Decode the unseen. //

We are certifying the first blood test for a treatable cause of Autism Spectrum Disorder (ASD) — the starting point to a generation of unsolved neurological conditions.

ASD is ever more prevalent

ASD now affects 1 in 31 children aged 8 years old in the US. Diagnosis rates have quadrupled since 2006 — and are still rising. Same picture for Europe.

4x

Higher ASD prevalence among population between 0-24 years in 2022 vs 2006

…and diagnostics can’t keep up

Families wait up to two years for a behavioural assessment. When a diagnosis finally arrives, there is no certified blood test to identify whether a treatable biological cause is involved — leaving children without the care they need.

That gap has a cost. And it has a solution.

Typical waiting time for ASD diagnosis in Germany

2y

Certified blood-based biomarker - diagnostic gap

No

Up to 4.1M patients

But there is a distinct, treatable ASD-subgroup: Cerebral Folate Deficiency (CFD)‍

With distinct biomarkers

CFD is fully attributable to a set of biomarkers, folate receptor auto-antibodies (FRAA)

Treatable

And treatment is underway - clear momentum for accessible companion diagnostics

Detectable? Now.

This is why Nevarra develops the first certified blood-based FRAA test‍ ‍